Checkpoint blockade in combination with cancer vaccines

Vaccine

Volumn 33, Issue 51, 2015, Pages 7377-7385

  Morse, Michael A ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti CTLA 4; Anti PD 1; Anti PD L1

Indexed keywords

CANCER VACCINE; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CELL CYCLE CHECKPOINT; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION;

ANIMALS; CANCER VACCINES; CTLA-4 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84955314743     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.057     Document Type: Article

References (97)

1. Tagliamonte M., Petrizzo A., Tornesello M.L., Buonaguro F.M., Buonaguro L. Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014, 10:3332-3346.
2. Patel S.P., Osada T., Lyerly H.K., Morse M.A. Designing effective vaccines for colorectal cancer. Immunotherapy 2014, 6(8):913-926.
3. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
4. Kantoff P.W., Schuetz T.J., Blumenstein B.A., Glode L.M., Bilhartz D.L., Wyand M., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28(March (7)):1099-1105.
5. Mittendorf E.A., Clifton G.T., Holmes J.P., Schneble E., van Echo D., Ponniah S., et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014, 25(September (9)):1735-1742.
6. Kroemer G., Zitvogel L., Galluzzi L. Victories and deceptions in tumor immunology: Stimuvax(®). Oncoimmunology 2013, 2(January (1)):e23687.
7. Sheikh N.A., Petrylak D., Kantoff P.W., Dela Rosa C., Stewart F.P., Kuan L.Y., et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013, 62(JANUARY (1)):137-147.
8. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18(August (8)):1254-1261.
9. Funt S.A., Page D.B., Wolchok J.D., Postow M.A. Ctla-4 antibodies: new directions, new combinations. Oncology (Williston Park) 2014, 28(November (11 Suppl. 3)). pii:202325.
10. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.
11. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000, 192:303-310. Cancer Immunol Immunother (2013) 62:245-56.
12. Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302.
13. Kavanagh B., O'Brien S., Lee D., Hou Y., Weinberg V., Rini B., et al. CTLA-4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008, 112:1175-1183.
14. O'Mahony D., Morris J.C., Quinn C., Gao W., Wilson W.H., Gause B., et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007, 13:958-964.
15. Liakou C.I., Kamat A., Tang D.N., Chen H., Sun J., Troncoso P., et al. CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008, 105:14987-14992.
16. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210(9):1695-1710.
17. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013, 1(1):32-42.
18. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322(October (5899)):271-275.
19. Leach D., Krummel M., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
20. Kwon E.D., Hurwitz A.A., Foster B.A., Madias C., Feldhaus A.L., Greenberg N.M., et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997, 94:8099-8103.
21. Hurwitz A.A., Yu T.F., Leach D.R., Allison J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998, 95(17):10067-10071.
22. Pauken K.E., Wherry E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015, (March). pii: S1471-4906(15)00039-3.
23. Thompson R.H., Dong H., Lohse C.M., Leibovich B.C., Blute M.L., Cheville J.C., et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007, 13:1757-1761.
24. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
25. Sierro S.R., Donda A., Perret R., Guillaume P., Yagita H., Levy F., et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 2011, 41(AUGUST (8)):2217-2228.
26. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, (JANUARY). pii: JCO.2014.59.4358. [Epub ahead of print].
27. Taube Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4(March (127)):127ra37.
28. Sawada Y. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol 2015, 46:28-36.
29. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571.
30. + T cells induced by melanoma vaccines. Cancer Res 2014, 74(February (4)):1045-1055.
31. Wong R.M., Scotland R.R., Lau R.L., Wang C., Korman A.J., Kast W.M., et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007, 19:1223-1234.
32. Egen J.G., Allison J.P. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002, 16:23.
33. Chambers C.A., Kuhns M.S., Egen J.G., Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001, 19:565.
34. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2(March (3)):261-268.
35. Brown J.A., Dorfman D.M., Ma F.R., Sullivan E.L., Munoz O., Wood C.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003, 170(FEBRUARY (3)):1257-1266.
36. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190(3):355-366.
37. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60(9):2444-2448.
38. Williams E.L., Dunn S.N., James S., Johnson P.W., Cragg M.S., Glennie M.J., et al. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res 2013, 19(July (13)):3545-3555.
39. Dos Santos L.I., Galvão-Filho B., de Faria P.C., Junqueira C., Dutra M.S., Teixeira S.M., et al. Blockade of CTLA-4 promotes the development of effector CD8(+) T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1. Cancer Immunol Immunother 2015, 64(March (3)):311-323.
40. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA-4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116(July (7)):1935-1945.
41. Avogadri F., Zappasodi R., Yang A., Budhu S., Malandro N., Hirschhorn-Cymerman D., et al. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res 2014, 2(May (5)):448-458.
42. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009, 206:3015-3029.
43. Amarnath S., Mangus C.W., Wang J.C., Wei F., He A., Kapoor V., et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011, 3:111ra20.
44. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003, 63(June (12)):3281-3288.
45. Jochems C., Tucker J.A., Tsang K.Y., Madan R.A., Dahut W.L., Liewehr D.J., et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 2014, 63(April (4)):407-418.
46. Espenschied J., Lamont J., Longmate J., Pendas S., Wang Z., Diamond D.J., et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003, 170(6):3401-3407.
47. Wada S., Jackson C.M., Yoshimura K., Yen H.R., Getnet D., Harris T.J., et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med 2013, 11:89.
48. Gregor P.D., Wolchok J.D., Ferrone C.R., Buchinshky H., Guevara-Patiño J.A., Perales M.A., et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004, 22(APRIL (3-14)):1700-1708.
49. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30(17):2046-2054.
50. Eggermont A.M., Chiarion-Sileni V., Grob J.J., Dummer R., Wolchok J.D., Schmidt H., et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial 2014, Presented at the 2014 Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; MAY 30-June 2, Abstract LBA9008.
51. Maker A.V., Attia P., Rosenberg S.A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005, 175:7746-7754.
52. Liakou C.I., Kamat A., Tang D.N., Chen H., Sun J., Troncoso P., et al. CTLA-4 blockade increases IFNg-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008, 105:14987-14992.
53. Ye J., Livergood R.S., Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 2013, 182(JANUARY (1)):10-20.
54. Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005, 23(FEBRUARY (4)):741-750.
55. Sarnaik A.A., Yu B., Yu D., Morelli D., Hall M., Bogle D., et al. Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011, 17:896-906.
56. Attia P., Phan G.Q., Maker A.V., Robinson M.R., Quezado M.M., Yang J.C., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-6053.
57. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(AUGUST (8)):711-723.
58. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003, 100(8):4712-4717.
59. Le D.T., Lutz E., Uram J.N., Sugar E.A., Onners B., Solt S., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013, 36(SEPTEMBER (7)):382-389.
60. Madan R.A., Mohebtash M., Arlen P.M., Vergati M., Rauckhorst M., Steinberg S.M., et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13(MAY (5)):501-508.
61. van den Eertwegh A.J., Versluis J., van den Berg H.P., Santegoets S.J., van Moorselaar R.J., van der Sluis T.M., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13(MAY (5)):509-517.
62. Santegoets S.J., Stam A.G., Lougheed S.M., Gall H., Scholten P.E., Reijm M., et al. T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013, 62(FEBRUARY (2)):245-256.
63. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Liénard D., Lejeune F., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004, 64(APRIL (8)):2865-2873.
64. + tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014, 124(MAY (5)):2246-2259.
65. Fu J., Malm I.J., Kadayakkara D.K., Levitsky H., Pardoll D., Kim Y.J. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014, 74(AUGUST (15)):4042-4052.
66. Soares K.C., Rucki A.A., Wu A.A., Olino K., Xiao Q., Chai Y., et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother 2015, 38(1):1-11.
67. Song M.Y., Park S.H., Nam H.J., Choi D.H., Sung Y.C. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother 2011, 34(APRIL (3)):297-306.
68. Wang W., Lau R., Yu D., Zhu W., Korman A., Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD41CD25Hi regulatory T cells. Int Immunol 2009, 21:1065-1077.
69. Mkrtichyan M., Najjar Y.G., Raulfs E.C., Abdalla M.Y., Samara R., Rotem-Yehudar R., et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent antitumor vaccine effects through novel mechanisms. Eur J Immunol 2011, 41:2977-2986.
70. del Rio M.L., Penuelas-Rivas G., Dominguez-Perles R., Ramirez P., Parrilla P., Rodriguez-Barbosa J.I. Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. Eur J Immunol 2005, 35:3545.
71. Karyampudi L., Lamichhane P., Scheid A.D., Kalli K.R., Shreeder B., Krempski J.W., et al. Accumulation of memory precursor CD8 Tlls in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 2014, 74(June (11)):2974-2985.
72. Ge Y., Xi H., Ju S., Zhang X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett 2013, 336(AUGUST (2)):253-259.
73. McGray A.J., Bernard D., Hallett R., Kelly R., Jha M., Gregory C., et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 2012, 1(JULY (4)):419-431.
74. Weber J.S., Kudchadkar R.R., Yu B., Gallenstein D., Horak C.E., Inzunza H.D., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013, 31(December (34)):4311-4318.
75. Gibney G.T., Kudchadkar R.R., DeConti R.C., Thebeau M.S., Czupryn M.P., Tetteh L., et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015, 21(FEBRUARY (4)):712-720.
76. Das R., Verma R., Sznol M., Boddupalli C.S., Gettinger S.N., Kluger H., et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015, 194(FEBRUARY (3)):950-959.
77. Duraiswamy J., Kaluza K.M., Freeman G.J., Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013, 73(June (12)):3591-3603.
78. Osada T., Patel S.P., Hammond S.A., Osada K., Morse M.A., Lyerly H.K. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother 2015, (March). [Epub ahead of print].
79. Zhou Q., Xiao H., Liu Y., Peng Y., Hong Y., Yagita H., et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol 2010, 185(NOVEMBER (9)):5082-5092.
80. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., Sabzevari H. Inhibition of CD4(1)251T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2682-2868. Crit Rev Immunol (2008) 28:109-26.
81. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344.
82. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194(6):823-832.
83. Sorensen M.R. Vaccine 2010, 28:6757-6764.
84. Vinay D.S., Kwon B.S. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep 2014, 47(3):122-129.
85. Shuford W.W., Klussman K., Tritchler D.D., Loo D.T., Chalupny J., Siadak A.W., et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186:47-55.
86. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002, 109:651-659.
87. Melero I., ShufordWW, Newby S.A., Aruffo A., Ledbetter J.A., Hellström K.E., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
88. Ju S.A., Lee S.C., Kwon T.H., Heo S.K., Park S.M., Paek H.N., et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour infiltrating lymphocytes. Immunol Cell Biol 2005, 83:344-351.
89. Gray J.C., French R.R., James S., Al-Shamkhani A., Johnson P.W., Glennie M.J. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol 2008, 38:2499-2511.
90. Miller R.E., Jones J., Le T., Whitmore J., Boiani N., Gliniak B., et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002, 169:1792-1800.
91. Li B., Lin J., Vanroey M., Jure-Kunkel M., Jooss K. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 2007, 125:76-87.
92. Cohen A.D., Diab A., Perales M.A., Wolchok J.D., Rizzuto G., Merghoub T., et al. Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity. Cancer Res 2006, 66:4904-4912.
93. Aida K., Miyakawa R., Suzuki K., Narumi K., Udagawa T., Yamamoto Y., et al. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer. Cancer Sci 2014, 105(2):159-167.
94. Mitsui J., Nishikawa H., Muraoka D., Wang L., Noguchi T., Sato E., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010, 16(10):2781-2791.
95. De Smedt T., Smith J., Baum P., Fanslow W., Butz E., Maliszewski C. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J Immunol 2002, 168(JANUARY (2)):661-670.
96. Murata S., Ladle B.H., Kim P.S., Lutz E.R., Wolpoe M.E., Ivie S.E., et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 2006, 176(JANUARY (2)):974-983.
97. Vu M.D., Xiao X., Gao W., Degauque N., Chen M., Kroemer A., et al. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007, 110:2501-2510.